AVLSA
VIGL

Atlas Venture Life Science Advisors’s Vigil Neuroscience VIGL Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio VIGL Stock Details VIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,836,874
Closed -$46.4M – 11
2025
Q2 		$46.4M Hold
5,836,874
– – 7.01% 6
2025
Q1 		$10.4M Hold
5,836,874
– – 1.99% 8
2024
Q4 		$9.92M Hold
5,836,874
– – 1.21% 7
2024
Q3 		$19.8M Hold
5,836,874
– – 1.84% 9
2024
Q2 		$23.3M Hold
5,836,874
– – 2.46% 9
2024
Q1 		$19.9M Hold
5,836,874
– – 1.84% 10
2023
Q4 		$19.7M Hold
5,836,874
– – 2.35% 8
2023
Q3 		$31.5M Hold
5,836,874
– – 4.87% 7
2023
Q2 		$54.9M Hold
5,836,874
– – 6.83% 5
2023
Q1 		$57.1M Hold
5,836,874
– – 7.74% 5
2022
Q4 		$73M Hold
5,836,874
– – 8.79% 4
2022
Q3 		$53.1M Hold
5,836,874
– – 5.86% 6
2022
Q2 		$15.1M Hold
5,836,874
– – 2.52% 9
2022
Q1 		$41M Buy
+5,836,874
New +$77M 5.19% 7

Other funds holding VIGL

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Atlas Venture Life Science Advisors's VIGL Position: Q3 2025 in Review

Atlas Venture Life Science Advisors sold out of Vigil Neuroscience (VIGL) in Q3 2025, closing a stake of 5,836,874 shares — an estimated $46.4M sold.

Atlas Venture Life Science Advisors first reported a position in VIGL in Q1 2022 and held it in 14 quarters. The position peaked at $73M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIGL as of Q3 2025.

  • Atlas Venture Life Science Advisors reported no remaining Vigil Neuroscience position as of Q3 2025 after selling out during the quarter.
  • Atlas Venture Life Science Advisors sold 5,836,874 Vigil Neuroscience shares in Q3 2025, an estimated $46.4M.
  • Atlas Venture Life Science Advisors first reported a position in Vigil Neuroscience in Q1 2022 and held it in 14 quarters.
  • Atlas Venture Life Science Advisors's Vigil Neuroscience position peaked at $73M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2025.

Based on Atlas Venture Life Science Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.